Get the Daily Brief
Latest Biotech News
Base editors hit the clinic: 23 programs now running — early activity seen
BioCentury reports that 23 base‑editor therapeutics have entered clinical development, with over half producing initial readouts that consistently show clinical activity. The tally spans in vivo...
Ventyx NLRP3 inhibitor posts striking Phase II biomarker drops — partner chatter
Ventyx Biosciences reported Phase II data for oral NLRP3 inhibitor VTX‑3232 showing rapid, large reductions in inflammatory biomarkers. The company said VTX‑3232 monotherapy cut hsCRP by roughly...
10x, Roche and Prognosys sue Illumina — spatial and single‑cell patents at issue
10x Genomics, joined by Roche Sequencing Solutions and Prognosys Biosciences, filed twin lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell...
Alector’s Phase III flop triggers program halt and staff cuts
Alector disclosed that a GSK‑partnered antibody failed its Phase III dementia study, prompting the company to stop development of that asset and cut roughly half its workforce. The failure follows...
FDA accepts IND supported solely by organoid efficacy — regulators shift
Qureator announced that the FDA approved an IND amendment for SillaJen’s combination therapy based solely on human vascularized organoid (vTIME) efficacy data — the first U.S. IND relying on...
Takeda buys global rights to Innovent’s oncology assets — $1.2bn upfront
Takeda signed a licensing and collaboration agreement with China’s Innovent Biologics to secure global rights outside Greater China to two late-stage oncology programs, committing $1.2 billion...
FDA grants limited return for GSK’s Blenrep — split approval narrows label
The U.S. Food and Drug Administration cleared GSK’s BCMA-targeting antibody–drug conjugate Blenrep for use in multiple myeloma under a narrowed approval: the agency authorized Blenrep in...
Moderna halts CMV vaccine program after Phase III failure — pivot to oncology
Moderna announced that its mRNA cytomegalovirus vaccine mRNA‑1647 failed to meet the primary efficacy endpoint in a large Phase III pivotal trial and will largely stop further development of the...
Base editors see 23 clinical programs — early readouts point to activity
Industry trackers report 23 distinct base‑editing programs have entered the clinic, with more than half producing initial clinical readouts showing consistent signals of activity. The landscape...
Ventyx’s oral NLRP3 inhibitor cuts inflammation biomarkers — investors take notice
Ventyx Biosciences reported Phase II data for oral NLRP3 inhibitor VTX‑3232 showing rapid, large reductions in high‑sensitivity C‑reactive protein (hsCRP) and other cardiovascular inflammation...
10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents
10x Genomics teamed with Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial biology and single‑cell...
Cellarity publishes AI‑driven cell‑state discovery framework in Science
Cellarity reported a new framework in Science describing how integrated transcriptomics and AI models can identify compounds that correct pathological cell states. The paper lays out a systematic...
Retrons repurposed for precise genome editing — new tools emerge
Researchers unveiled retron‑based gene‑editing platforms that use bacterial reverse transcriptases to synthesize donor single‑stranded DNA intracellularly, enabling precise insertion and editing...
FDA accepts IND based solely on human vascularized organoid efficacy data — first‑ever
Qureator announced that the FDA has cleared an IND for SillaJen’s BAL0891 combination based primarily on efficacy data generated with Qureator’s vascularized tumor immune microenvironment (vTIME)...
Regeneron halts 2seventy‑acquired CAR‑T bbT369 — program dropped
Regeneron confirmed it has stopped development of bbT369, a dual‑targeting CAR‑T therapy (CD79a/CD20) acquired through its 2024 purchase of 2seventy bio’s pipeline. The company halted the phase...
FDA reinstates GSK’s Blenrep — approval narrowed to Velcade combo
The FDA cleared GlaxoSmithKline’s BCMA-targeting antibody–drug conjugate Blenrep to return to the U.S. market with a restricted label. The agency approved Blenrep for use in combination with...
Moderna’s CMV vaccine fails Phase 3 — company halts most development
Moderna announced that its phase III trial of the mRNA‑1647 cytomegalovirus (CMV) vaccine missed its primary efficacy endpoints and will largely stop further development of the program. The...
Ventyx’s NLRP3 data: biomarker collapse and a market fever
Ventyx Biosciences reported Phase 2 data showing its oral NLRP3 inhibitor VTX3232 produced rapid, large reductions in inflammatory biomarkers in patients with obesity and cardiovascular risk...
10x, Roche and Prognosys sue Illumina: patent fight targets spatial and single‑cell tech
10x Genomics partnered with Roche Sequencing Solutions and Prognosys Biosciences to file twin lawsuits accusing Illumina of infringing nine patents tied to spatial transcriptomics and single‑cell...
Cellarity publishes cell‑state drug framework in Science — AI maps new discovery route
Cellarity published a manuscript in Science describing a framework that fuses transcriptomic datasets with AI modeling to discover ‘cell state‑correcting’ medicines. The company outlined methods...